Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed metastatic or surgically unresectable solid tumor meeting 1 of the following criteria:
• •* Any solid tumor (Phase I)
• •* Adenocarcinoma of the stomach or gastroesophageal junction (Phase II)
• •Unidimensionally measurable disease by CT scan or MRI
• •No uncontrolled brain metastasis
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-1
• •ANC ≥ 1,500/mm³
• •Platelet count ≥ 100,000/mm³
• •Hemoglobin ≥ 8.0 g/dL
• •Creatinine ≤ 1.5 times upper limit of normal (ULN)
• •Total bilirubin normal
• •Meets 1 of the following criteria:
• •* Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times ULN
• •* AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
• •* AP ≤ 5 times ULN AND AST or ALT normal
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for ≥ 3 months after completion of study therapy
• •No preexisting neuropathy
• •No concurrent uncontrolled illness or other condition that would preclude study compliance
• •No history of severe hypersensitivity reaction to docetaxel or to other drugs formulated with polysorbate 80
• •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study
• •PRIOR CONCURRENT THERAPY:
• •Recovered from prior therapy
• •More than 4 weeks since prior therapy (Phase I)
• •No prior oxaliplatin or taxanes (Phase I)
• •More than 4 weeks since prior radiotherapy (Phase I)
• •No more than two prior therapies for metastatic disease (Phase I)
• •No prior therapy for metastatic disease (Phase II)
• •At least 6 months since prior adjuvant therapy (given prior to the occurrence of metastatic disease) (Phase II)
• •Prior fluorouracil and concurrent radiotherapy for palliation of the primary tumor allowed provided metastatic disease is present outside the radiotherapy field (Phase II)
• •No prior radiotherapy to ≥ 30% of bone marrow
• •No other concurrent investigational agents